You are here: Industry Insights > AstraZeneca

News List

AstraZeneca Presents New Data Evaluating Safety and Efficacy of FARXIGA in Patients with Type 2 Diab biospace AstraZeneca today announced the results o
March 20, 2018
AstraZeneca today announced the results of DERIVE, a Phase 3 study that evaluated the efficacy and safety of FARXIGA®(dapagliflozin 10 mg), in patients with type 2 diabetes (T2D) with moderate renal impairment
SGLT-2 inhibitors cut risk of death in diabetics, data shows pharmatimes
March 14, 2018
AstraZeneca has unveiled findings of a new analysis of data from the CVD-REAL study, showing a significant cut in the risk of all-cause death (ACD) in patients with type II diabetes taking SGLT-2 inhibitors.
AZ announces results delay for key lung cancer trial pharmatimes
March 13, 2018
AstraZeneca and research arm MedImmune have announced a longer wait for survival data from a closely-watched trial testing Imfinzi in advanced lung cancer.
AstraZeneca’s drugs with potential in 2018 Shulin Yang
February 12, 2018
The pharmaceutical product sales of AstraZeneca declined by 5% in 2017, to which Onglyza, Symbicort, and Crestor, etc. could be said to have made “big contributions”.
AstraZeneca:2018 Sale Directions from 2017 Financial Report and Chinese Market Shulin Yang
February 12, 2018
Global pharmaceutical enterprises have successively published their 2017 financial reports recently, and there were good and poor results
AstraZeneca allies with Alibaba and Tencent as its China sales soar fiercepharma
February 05, 2018
AstraZeneca is now stepping up its game there through two new deals with Chinese internet giants Alibaba and Tencent.
Syndax Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca americanpharmaceuticalreview
February 02, 2018
Syndax Pharmaceuticals Announces New Clinical Partnership with AstraZeneca
AZ’ triple combo COPD inhaler hits PhIII targets pharmatimes
January 31, 2018
AstraZeneca recently unveiled top-line trial data backing use of an experimental triple combination therapy being developed for use with its Aerosphere technology in patients with chronic obstructive pulmonary disease (COPD).
AZ’s triple therapy inhaler hits 8 out of 9 endpoints pharmafile
January 29, 2018
AstraZeneca has made a brief announcement that its triple therapy inhaler manage to successfully hit eight of nine primary endpoints in the treatment of moderate to very severe chronic obstructive pulmonary disease (COPD).
AstraZeneca's Three-in-One COPD Inhaler Succeeds in Phase III Trial biospace
January 29, 2018
AstraZeneca has GlaxoSmithKline and its chronic obstructive pulmonary disease (COPD) treatment Trelegy Ellipta squarely in its sights.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page